Related Experiment Videos
System for simultaneous tissue-specific and disease-specific regulation of therapeutic gene expression
Yung H Chyung1, Peter D Peng, Mark A Kay
1Department of Pediatrics and Genetics, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Abstract:
Gene therapy has been proposed as an alternative strategy for treating nongenetic disorders, such as cancer and coronary artery disease. However, for many of these types of diseases, the therapeutic genes must be tightly regulated, as extensive toxicity and pathology can result if their expression is not adequately controlled. Toward this end, we have developed a regulatory system in which the expression of a therapeutic transgene is controlled simultaneously by both a tissue-specific promoter and a disease-specific promoter. Thus, the transgene of interest will be expressed in a given cell only if both of these promoters are active. Unlike many other transgene-regulatory systems that have been previously developed, this system does not require the persistent expression of any foreign genes that could provoke an immune response or lead to toxicity. As proof of concept, we synthesized a construct harboring the lacZ transgene that is under the control of both the hepatocyte-specific human alpha(1)-antitrypsin promoter and the zinc-inducible mouse metallothionein promoter. We show that reporter gene expression from this construct is regulated in both a hepatocyte-specific and zinc-regulated manner, as reporter gene expression occurs only in hepatocyte-derived cells that have been exposed to zinc. The improved regulation offered by our system would facilitate the targeting of transgene expression to sites of disease in the body and spare healthy tissue, thereby considerably enhancing the therapeutic window of gene therapy.
Insights
This study introduces a novel gene therapy regulation system. It uses dual promoters for precise control, enhancing safety and efficacy in treating diseases like cancer.
Area of Science:
- Molecular Biology
- Gene Therapy
- Biotechnology
Background:
- Gene therapy offers potential for non-genetic disorders but requires strict gene expression control to prevent toxicity.
- Existing regulatory systems may provoke immune responses or toxicity due to persistent foreign gene expression.
Purpose of the Study:
- To develop a novel, tightly regulated gene expression system for therapeutic transgenes.
- To ensure transgene expression is confined to specific tissues and disease states, minimizing off-target effects.
Main Methods:
- Designed a dual-promoter system combining a tissue-specific promoter (human alpha(1)-antitrypsin) and a disease-specific promoter (mouse metallothionein).
- Constructed a reporter gene (lacZ) under the control of this dual-promoter system.
- Validated the system's specificity and inducibility in hepatocyte-derived cells exposed to zinc.
Main Results:
- Reporter gene expression was successfully regulated in a hepatocyte-specific manner.
- Expression was also precisely controlled by the presence of zinc, demonstrating inducibility.
- Functional reporter gene expression occurred only in zinc-exposed hepatocyte cells.
Conclusions:
- The developed dual-promoter system offers improved control over transgene expression.
- This system enhances targeting to disease sites and spares healthy tissues, expanding the therapeutic window.
- It avoids persistent foreign gene expression, reducing potential immune reactions and toxicity.